Nanobiotix is a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing innovative product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles. NBTXR3 is being investigated for the treatment of multiple cancers, including soft tissue sarcoma, head and neck cancer, liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand.
On which stock exchange is Nanobiotix (NBTX) listed and in what currency?
Nanobiotix S.A. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NBTX. The stock trades in US dollars (USD). Although the company is headquartered in France, it is listed on a US exchange, which allows investors in the United States and globally to trade its shares in USD.
What sector and industry does Nanobiotix (NBTX) operate in?
Nanobiotix operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies, particularly in oncology. Its lead candidate, NBTXR3, is a nanoparticle-based product designed to enhance the efficacy of radiotherapy in cancer treatment. The company is clinical-stage, meaning its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.
Where is Nanobiotix headquartered and what markets does it serve?
Nanobiotix S.A. is headquartered in Paris, France, and was incorporated in 2003. While the company is based in Europe, it has a global reach through its partnership with Lian Oncology Limited, which covers the development and commercialization of NBTXR3 in China, South Korea, Singapore, and Thailand. This partnership allows Nanobiotix to expand its presence in key Asian markets. The company's clinical trials and potential future products target patients worldwide, particularly those with various solid tumors.
What is Nanobiotix's (NBTX) business model and how does it generate revenue?
As a clinical-stage biotechnology company, Nanobiotix does not yet have any approved products on the market, so it does not generate revenue from product sales. Its business model focuses on research and development of its lead candidate, NBTXR3, and other potential therapies. The company may generate revenue through partnerships and licensing agreements, such as its collaboration with Lian Oncology Limited, which provides milestones and royalties from the development and commercialization of NBTXR3 in specified Asian territories. Additionally, Nanobiotix may seek further partnerships or funding to advance its pipeline.